Skip to Main Content

Paper Details

A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs.
Mult Scler J Exp Transl Clin
9
2018
Author NameAffiliation
James D BowenSwedish Neuroscience Institute
  • 1 - 1

Datasets

Release 1.2